BOLT - CIK 0001641281
Bolt Biotherapeutics, Inc. trades as BOLT. In its fiscal 2025 annual report the company posted revenue of $7.70M, up 0.1% from the prior year and net income of -$33.38M. This page tracks Bolt Biotherapeutics, Inc. through 278 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Bolt Biotherapeutics, Inc.'s revenue grew from $231.00K to $7.70M, a compound annual growth rate of 101.6%. Net profit margin expanded from -26289.2% to -433.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| Employee stock plan | S-8 | 2026-03-12 |
| Annual report | 10-K | 2026-03-12 |
| Major company event | 8-K | 2026-03-12 |
The largest companies sharing Bolt Biotherapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Bolt Biotherapeutics, Inc. reported revenue of $7.70M for fiscal year 2025, an increase of 0.1% year over year.
In its latest fiscal year Bolt Biotherapeutics, Inc. reported a net loss of $33.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.